Background and Purpose-The efficacy of neuroprotective approaches in stroke may be influenced by existing comorbidities. Here, we compared the effects of normobaric hyperoxia (NBO) in normotensive versus hypertensive rats subjected to transient focal cerebral ischemia. Methods-Male Sprague-Dawley and spontaneously hypertensive rats were subjected to transient focal ischemia via intraluminal filament occlusions of the middle cerebral artery. NBO was started 15 minutes after ischemic onset and stopped at the time of reperfusion. Acute neurological deficits and tetrazolium-stained infarct volumes were quantified at 24 hours. Results-NBO reduced mean infarct volumes by ≈50% (P=0.0064) in normotensive Sprague-Dawley rats subjected to 100 minutes transient ischemia. No effects of NBO were observed in hypertensive spontaneously hypertensive rats subjected to either 100 minutes or 75 minutes of transient ischemia. No significant changes in neurological outcomes were detectable in any group. Conclusions-NBO reduced infarction in Sprague-Dawley but not in spontaneously hypertensive rats. These findings suggest that comorbidities may influence responses to potential treatments after stroke. Visual Overview-An online visual overview is available for this article.
R ecent recommendations for translational stroke research emphasize the importance of comorbidities in animal models. 1 The majority of experimental studies in stroke research uses young healthy rodents. In contrast, the typical stroke patient may be older with an array of associated vascular conditions. Here, we asked whether hypertension, a common feature in many stroke patients, might influence therapeutic outcomes in a rat model of focal cerebral ischemia. Of course, there are many potential targets and therapies for ischemic stroke. In this proof-of-concept study, we tested normobaric hyperoxia (NBO) because it may affect multiple mechanisms, it is relatively easy to administer, and we have previous experience for this approach.
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Methods
All data are included in Results and in the online-only Data Supplement.
Animal Models
All procedures followed institutionally approved protocols. Adult male Sprague-Dawley (SD) rats (300-320 g, Charles River) and adult male spontaneously hypertensive (SHR) rats (280-300 g, Charles River) were subjected to the standard intraluminal filament model of focal cerebral ischemia under isofluorane anesthesia and laser doppler-flow monitoring. 5 All animals (n=12 per group) were randomly and blindly treated with NBO (100% oxygen) or 30%/70% oxygen/nitrogen for controls, starting at 15 minutes post-ischemia and stopped at onset of reperfusion. Full details are available in Methods in the online-only Data Supplement.
Outcomes
After 24 hours, rats were neurologically assessed (modified Neurological Severity Score, neuroscore, and body swing test) and then brains extracted for tetrazolium staining of infarct volumes. 5 Data were assessed with analysis of variable for multigroup comparisons or t-tests for 2-group comparisons. Neurological outcomes were analyzed using Mann-Whitney test. Full details given in Methods in the online-only Data Supplement.
Results
Except for Po 2 , physiological parameters were maintained within similar ranges for all animals (Table) . As expected, NBO increased Po 2 above 400 mm Hg during ischemia, compared with controls in all 3 experiments (Table) .
In Experiment 1, 100 minutes of transient focal ischemia led to well-defined infarcts in SD rats (23.02±7.7). NBO treatments did not affect laser doppler-flow levels of ischemia-reperfusion but reduced mean infarct volumes by ≈50% (12.69±9.04; P=0.0064; Figure 1A ). In Experiment 2, 100 minutes of transient occlusion in SHR rats also induced the expected profiles of ischemia, reperfusion, and infarction (31.93±6.0; Figure 1B ). But NBO did not alter mean infarct sizes in SHR rats (29.67±7.1; P=0.4091; Figure 1B ). Because infarcts were larger in SHR rats (Experiment 2) compared with SD rats (Experiment 1), we decided to assess a shorter period of occlusion to see whether NBO might work in SHR rats if the original injury was less severe. In Experiment 3, 75 minutes of transient occlusion in SHR rats resulted in ischemia-reperfusion profiles and infarct sizes that were comparable to those obtained in SD rats (22.56±7.3; Figure 1C ). However, NBO still did not alter mean infarct sizes (23.75±8.5; P=0.7165; Figure 1C) .
In contrast to the infarct volume data, NBO did not seem to alter neurological outcomes in modified Neurological Severity Score, neuroscore, or body swing tests in any of the groups tested (Figure 2 ).
Discussion
Timely reperfusion with tissue-type plasminogen activator can improve outcomes in acute ischemic stroke. More recently, several endovascular trials suggest that clot retrieval with thrombectomy devices may also recanalize large vessels and improve outcomes in selected patients. Taken together, the efficacy of acute reperfusion may now compel us to revisit the idea of neuroprotection. 6 Then the goal would be to find neuroprotectants that amplify reperfusion efficacy, extend the reperfusion window, and convert nonresponders into responders. When revisiting neuroprotective hypotheses, it may be useful to consider lessons learned from previous translational efforts. Protecting only neurons may not suffice; targets and mechanisms should include all cell types in the neurovascular unit. 1, 7 Quality control must be rigorously applied during preclinical testing. 1 And perhaps most importantly, animal models should more closely mimic the clinical situation. 1 The typical model of focal cerebral ischemia uses healthy young rodents. The typical stroke patient may be older with vascular comorbidities.
Here, we compared NBO (breathing 100% normobaric oxygen) in normotensive SD rats versus hypertensive SHR rats. But why test NBO among so many putative approaches? NBO is known to affect multifactorial pathways in the neurovascular unit, including improvement of penumbral hypoxia, metabolic rescue, dampening of matrix metalloproteases, rescue of the blood-brain barrier, and amelioration of inflammation. 2, 4, 8, 9 So, we used NBO in part because of its nonspecific effects. Furthermore, NBO may freeze the penumbra 10 and extend the time window for reperfusion, 3 so it may fit well with endovascular thrombectomy procedures. Consistent with the literature, we found that NBO reduced acute infarction in SD rats subjected to 100 minutes transient focal cerebral ischemia. But no decrease in infarction was detected in SHR rats subjected to a similar 100 minutes occlusion. Because ischemia is known to be more severe in SHR rats, we assessed a shorter ischemic period of 75 minutes that led to smaller infarct volumes comparable with those obtained in SD rats (where NBO worked). However, NBO still did not seem to alter mean infarct sizes in SHR rats subjected to shorter ischemic periods. These negative findings differ from a previous study suggesting efficacy of NBO in SHR rats after short periods of focal ischemia using a distal occlusion of the middle cerebral artery, 9 suggesting that NBO effects may depend on ischemic severity. NBO was safe and feasible in an initial clinical trial, 11 although a larger trial was prematurely stopped before yielding conclusive data (terminated; imbalance in deaths favoring control arm; deaths not attributed to treatment; http://clinicaltrials.gov). It is interesting to speculate whether NBO protocols optimized in comorbid animal models may offer better chances for successful translation. In general, our results may agree with previous observations regarding the importance of comorbidities in animal models. For example, protective effects of IGF-1 were reduced in hypertensive compared with normotensive rats, 12 and N-methyl-D-aspartic acid/α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid antagonists decreased ischemic brain damage in young but not old rats. 13 Taken together, this study suggests that NBO therapeutic response may be affected by hypertension. Nevertheless, there are several caveats. First, we only looked at 24 hours neurological end points and may have missed potential differences during longer periods of recovery. Nevertheless, it is not our purpose to reassess the large literature on NBO neuroprotection in normal rodents, but instead we aim to show that NBO effects may be influenced by hypertension. Second, the underlying mechanisms remain unclear. The ischemic penumbra may be smaller in SHR compared with SD rats, perhaps because of the effects of hypertension on arteriole structure and collateral supply.
14 Our singlepoint laser-doppler method may have missed potential differences in ischemia-reperfusion. It has also been suggested that endothelial dysfunction may render the cerebrovascular system of apolipoprotein E or endothelial nitric oxide synthase knockout mice nonresponsive to NBO. 15 Third, we only tested one NBO dose. Whether other higher dose protocols may work (eg, extending NBO into reperfusion) remains to be determined. Finally, we used male rats. Further studies are needed to examine the effects of sex.
The present findings suggest that infarct reduction after NBO may be different in hypertensive compared with normotensive rats. We do not conclude that NBO does not translate for stroke. Instead, this proof-of-concept study emphasizes that any therapeutic approach should be assessed and adjusted for animal models that include common comorbidities found in stroke patients.
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